Evercore ISI analyst Vijay Kumar lowered the firm’s price target on Edwards Lifesciences (EW) to $92 from $94 and keeps an Outperform rating on the shares as part of the firm’s medical technology and life science tools Q1 preview.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EW:
- Disney upgraded, Nike downgraded: Wall Street’s top analyst calls
- Edwards Lifesciences upgraded to Outperform from Peer Perform at Wolfe Research
- Edwards Lifesciences: TRISCEND II Data and EVOQUE Differentiation Underpin Buy Rating and Long-Term Growth Outlook
- Edwards Lifesciences announces new data on EVOQUE TTVR system
- Oppenheimer downgrades AtriCure on new competition from Edwards